{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:10Z","timestamp":1785526810952,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["BJ-2023-105"],"award-info":[{"award-number":["BJ-2023-105"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["BJ-2022-115"],"award-info":[{"award-number":["BJ-2022-115"]}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2025-I2M-C&T-B-093"],"award-info":[{"award-number":["2025-I2M-C&T-B-093"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2023-JKCS-22"],"award-info":[{"award-number":["2023-JKCS-22"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07947-7","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:18:58Z","timestamp":1779520738000},"page":"5795-5810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An interpretable 1\u2078F-PSMA PET\/CT\u2013MRI model for optimizing prostate biopsy decisions"],"prefix":"10.1007","volume":"53","author":[{"given":"Shuaitao","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengtong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longteng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4770-4449","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"2","key":"7947_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"issue":"10071","key":"7947_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1.","journal-title":"Lancet"},{"issue":"19","key":"7947_CR3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767\u201377. https:\/\/doi.org\/10.1056\/NEJMoa1801993.","journal-title":"N Engl J Med"},{"issue":"17","key":"7947_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14171864","volume":"14","author":"G Rebez","year":"2024","unstructured":"Rebez G, Barbiero M, Simonato FA, et al. Targeted prostate biopsy: how, when, and why? A systematic review. Diagnostics. 2024;14(17):1864. https:\/\/doi.org\/10.3390\/diagnostics14171864.","journal-title":"Diagnostics"},{"issue":"1","key":"7947_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen AC, McCulloch CE, Anaokar JM, et al. Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020;296(1):76\u201384. https:\/\/doi.org\/10.1148\/radiol.2020190646.","journal-title":"Radiology"},{"issue":"10231","key":"7947_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"issue":"6","key":"7947_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80(6):682\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.002.","journal-title":"Eur Urol"},{"issue":"1","key":"7947_CR8","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/RLU.0000000000005501","volume":"50","author":"P Aggarwal","year":"2025","unstructured":"Aggarwal P, Gunasekaran V, Singh H, Kumar R, Satapathy S, Mittal BR. Diagnostic accuracy of PSMA PET-guided prostate biopsy in prostate cancer-a systematic review and meta-analysis. Clin Nucl Med. 2025;50(1):e26-33. https:\/\/doi.org\/10.1097\/RLU.0000000000005501.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"7947_CR9","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, et al. The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63(11):1644\u201350. https:\/\/doi.org\/10.2967\/jnumed.121.263448.","journal-title":"J Nucl Med"},{"key":"7947_CR10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266742","author":"J Shi","year":"2024","unstructured":"Shi J, Li D, Chen M, et al. The value of 68 Ga-PSMA PET\/MRI for classifying patients with PI-RADS 3 lesions on multiparametric MRI: a prospective single-center study. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.123.266742.","journal-title":"J Nucl Med"},{"key":"7947_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s00259-024-06916-2","volume":"52","author":"S Guo","year":"2025","unstructured":"Guo S, Ren J, Meng Q, et al. The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:756\u201365. https:\/\/doi.org\/10.1007\/s00259-024-06916-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7947_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2022.825512","volume":"2","author":"N Malan","year":"2022","unstructured":"Malan N, Vangu MdiT. Normal variants, pitfalls, and artifacts in Ga-68 prostate specific membrane antigen (PSMA) PET\/CT imaging. Front Nucl Med. 2022;2:825512. https:\/\/doi.org\/10.3389\/fnume.2022.825512.","journal-title":"Front Nucl Med"},{"issue":"12","key":"7947_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141.","journal-title":"Nat Rev Clin Oncol"},{"key":"7947_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103544","volume":"169","author":"S Ghezzo","year":"2022","unstructured":"Ghezzo S, Bezzi C, Presotto L, et al. State of the art of radiomic analysis in the clinical management of prostate cancer: a systematic review. Crit Rev Oncol Hematol. 2022;169:103544. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103544.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"7947_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00259-021-05430-z","volume":"49","author":"EL Solari","year":"2022","unstructured":"Solari EL, Gafita A, Schachoff S, et al. The added value of PSMA PET\/MR radiomics for prostate cancer staging. Eur J Nucl Med Mol Imaging. 2022;49(2):527\u201338. https:\/\/doi.org\/10.1007\/s00259-021-05430-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7947_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00936-5","volume":"12","author":"S Zang","year":"2022","unstructured":"Zang S, Ai S, Yang R, et al. Development and validation of 68Ga-PSMA-11 PET\/CT-based radiomics model to detect primary prostate cancer. EJNMMI Res. 2022;12(1):63. https:\/\/doi.org\/10.1186\/s13550-022-00936-5.","journal-title":"EJNMMI Res"},{"issue":"1","key":"7947_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-00984-5","volume":"13","author":"TH Chan","year":"2023","unstructured":"Chan TH, Haworth A, Wang A, et al. Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy. EJNMMI Res. 2023;13(1):34. https:\/\/doi.org\/10.1186\/s13550-023-00984-5.","journal-title":"EJNMMI Res"},{"issue":"8","key":"7947_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00259-023-06187-3","volume":"50","author":"S Ghezzo","year":"2023","unstructured":"Ghezzo S, Mapelli P, Bezzi C, et al. Role of [68Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(8):8. https:\/\/doi.org\/10.1007\/s00259-023-06187-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7947_CR19","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/bioinformatics\/btq134","volume":"26","author":"A Altmann","year":"2010","unstructured":"Altmann A, Tolo\u015fi L, Sander O, Lengauer T. Permutation importance: a corrected feature importance measure. Bioinformatics. 2010;26(10):1340\u20137. https:\/\/doi.org\/10.1093\/bioinformatics\/btq134.","journal-title":"Bioinformatics"},{"issue":"16","key":"7947_CR20","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.1021\/acs.jmedchem.9b01101","volume":"63","author":"R Rodr\u00edguez-P\u00e9rez","year":"2020","unstructured":"Rodr\u00edguez-P\u00e9rez R, Bajorath J. Interpretation of compound activity predictions from complex machine learning models using local approximations and Shapley values. J Med Chem. 2020;63(16):8761\u201377. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01101.","journal-title":"J Med Chem"},{"issue":"3","key":"7947_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033.","journal-title":"Eur Urol"},{"issue":"8","key":"7947_CR22","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.7150\/thno.103667","volume":"15","author":"X Cheng","year":"2025","unstructured":"Cheng X, Hou G, Wang M, et al. Clinical value of [18F]AlF-Thretide PET\/CT and early-time-point PET acquisition in the detection and staging of prostate cancer. Theranostics. 2025;15(8):3643\u201354. https:\/\/doi.org\/10.7150\/thno.103667.","journal-title":"Theranostics"},{"issue":"7","key":"7947_CR23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.123.266940","volume":"65","author":"J Zang","year":"2024","unstructured":"Zang J, Yang Y, Chen S, et al. Diagnostic performance of [18F]AlF-Thretide PET\/CT in patients with newly diagnosed prostate cancer using histopathology as reference standard. J Nucl Med. 2024;65(7):1021\u20136. https:\/\/doi.org\/10.2967\/jnumed.123.266940.","journal-title":"J Nucl Med"},{"issue":"9","key":"7947_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2967\/jnumed.118.221671","volume":"60","author":"T Liu","year":"2019","unstructured":"Liu T, Liu C, Xu X, et al. Preclinical evaluation and pilot clinical study of Al18F-PSMA-BCH for prostate cancer PET imaging. J Nucl Med. 2019;60(9):1284\u201392. https:\/\/doi.org\/10.2967\/jnumed.118.221671.","journal-title":"J Nucl Med"},{"issue":"16","key":"7947_CR25","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78(16):4786\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0125.","journal-title":"Cancer Res"},{"issue":"2","key":"7947_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328\u201338. https:\/\/doi.org\/10.1148\/radiol.2020191145.","journal-title":"Radiology"},{"issue":"7","key":"7947_CR27","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00259-023-06136-0","volume":"50","author":"A Basso Dias","year":"2023","unstructured":"Basso Dias A, Mirshahvalad SA, Ortega C, et al. The role of [18F]-DCFPyL PET\/MRI radiomics for pathological grade group prediction in prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(7):2167\u201376. https:\/\/doi.org\/10.1007\/s00259-023-06136-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7947_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06734-6","volume":"51","author":"T Li","year":"2024","unstructured":"Li T, Xu M, Yang S, et al. Development and validation of [18F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51(9):9. https:\/\/doi.org\/10.1007\/s00259-024-06734-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7947_CR29","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1007\/s00259-025-07248-5","volume":"52","author":"J Jiang","year":"2025","unstructured":"Jiang J, Fan Z, Jiang S, et al. Interpretable multimodal deep learning model for predicting post-surgical International Society of Urological Pathology grade in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(10):3730\u201343. https:\/\/doi.org\/10.1007\/s00259-025-07248-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7947_CR30","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7947_CR31","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","volume":"87","author":"E Mazzone","year":"2025","unstructured":"Mazzone E, Cannoletta D, Quarta L, et al. A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment. Eur Urol. 2025;87(6):654\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.003.","journal-title":"Eur Urol"},{"issue":"10","key":"7947_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101897","volume":"16","author":"LM Huynh","year":"2024","unstructured":"Huynh LM, Swanson S, Cima S, Haddadin E, Baine M. Prostate-specific membrane antigen positron emission tomography\/computed tomography-derived radiomic models in prostate cancer prognostication. Cancers (Basel). 2024;16(10):1897. https:\/\/doi.org\/10.3390\/cancers16101897.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"7947_CR33","doi-asserted-by":"publisher","first-page":"7909","DOI":"10.1007\/s00330-024-10818-0","volume":"34","author":"A Schrader","year":"2024","unstructured":"Schrader A, Netzer N, Hielscher T, et al. Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomograms. Eur Radiol. 2024;34(12):7909\u201320. https:\/\/doi.org\/10.1007\/s00330-024-10818-0.","journal-title":"Eur Radiol"},{"issue":"2","key":"7947_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.urolonc.2018.11.021","volume":"37","author":"JFM Verbeek","year":"2019","unstructured":"Verbeek JFM, Bangma CH, Kweldam CF, et al. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Urol Oncol. 2019;37(2):138\u201344. https:\/\/doi.org\/10.1016\/j.urolonc.2018.11.021.","journal-title":"Urol Oncol"},{"issue":"6","key":"7947_CR35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/JU.0000000000001306","volume":"204","author":"KJ Park","year":"2020","unstructured":"Park KJ, Choi SH, Lee JS, Kim JK, Kim MH, Jeong IG. Risk stratification of prostate cancer according to PI-RADS\u00ae version 2 categories: meta-analysis for prospective studies. J Urol. 2020;204(6):1141\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000001306.","journal-title":"J Urol"},{"issue":"3","key":"7947_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4258","volume":"7","author":"A Haj-Mirzaian","year":"2024","unstructured":"Haj-Mirzaian A, Burk KS, Lacson R, et al. Magnetic resonance imaging, clinical, and biopsy findings in suspected prostate cancer: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(3):e244258. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.4258.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"7947_CR37","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3631-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7947_CR38","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.7150\/thno.32376","volume":"9","author":"C Zamboglou","year":"2019","unstructured":"Zamboglou C, Carles M, Fechter T, et al. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics. 2019;9(9):2595\u2013605. https:\/\/doi.org\/10.7150\/thno.32376.","journal-title":"Theranostics"},{"issue":"3","key":"7947_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1148\/radiol.2015142414","volume":"277","author":"A Chatterjee","year":"2015","unstructured":"Chatterjee A, Watson G, Myint E, Sved P, McEntee M, Bourne R. Changes in epithelium, stroma, and lumen space correlate more strongly with Gleason pattern and are stronger predictors of prostate ADC changes than cellularity metrics. Radiology. 2015;277(3):751\u201362. https:\/\/doi.org\/10.1148\/radiol.2015142414.","journal-title":"Radiology"},{"issue":"9","key":"7947_CR40","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s00259-025-07190-6","volume":"52","author":"BM Priv\u00e9","year":"2025","unstructured":"Priv\u00e9 BM, Govers TM, Isra\u00ebl B, et al. A cost-effectiveness study of PSMA-PET\/CT for the detection of clinically significant prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(9):3159\u201369. https:\/\/doi.org\/10.1007\/s00259-025-07190-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7947_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","volume":"79","author":"RE de Feria Cardet","year":"2021","unstructured":"de Feria Cardet RE, Hofman MS, Segard T, et al. Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial. Eur Urol. 2021;79(3):413\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.043.","journal-title":"Eur Urol"},{"issue":"1","key":"7947_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22594-1","volume":"8","author":"S Bravaccini","year":"2018","unstructured":"Bravaccini S, Puccetti M, Bocchini M, et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 2018;8(1):4254. https:\/\/doi.org\/10.1038\/s41598-018-22594-1.","journal-title":"Sci Rep"},{"issue":"4","key":"7947_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469\u201378. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030.","journal-title":"Eur Urol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07947-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07947-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:03:56Z","timestamp":1785521036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07947-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7947"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07947-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study was approved by the Institutional Review Board of Beijing Hospital (2022BJYYEC-198\u201302) and the Institutional Review Board of Peking University First Hospital (2023\u2013164-001).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained for each patient.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}